Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.

Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators.

N Engl J Med. 2017 Apr 20;376(16):1527-1539. doi: 10.1056/NEJMoa1701488. Epub 2017 Mar 17.

PMID:
28304242
2.

Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.

Brinton EA, Kher U, Shah S, Cannon CP, Davidson M, Gotto AM, Ashraf TB, McCrary Sisk C, Dansky H, Mitchel Y, Barter P; DEFINE Investigators.

J Clin Lipidol. 2015 Jan-Feb;9(1):65-71. doi: 10.1016/j.jacl.2014.10.005. Epub 2014 Nov 4.

PMID:
25670362
3.

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM; BEACON Trial Investigators.

N Engl J Med. 2013 Dec 26;369(26):2492-503. doi: 10.1056/NEJMoa1306033. Epub 2013 Nov 9.

4.

Safety of anacetrapib in patients with or at high risk for coronary heart disease.

Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P; Determining the Efficacy and Tolerability Investigators.

N Engl J Med. 2010 Dec 16;363(25):2406-15. doi: 10.1056/NEJMoa1009744. Epub 2010 Nov 17.

5.

Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.

Cannon CP, Dansky HM, Davidson M, Gotto AM Jr, Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P; DEFINE investigators.

Am Heart J. 2009 Oct;158(4):513-519.e3. doi: 10.1016/j.ahj.2009.07.028.

PMID:
19781408
6.

Exenatide (exendin-4)-induced pancreatitis: a case report.

Denker PS, Dimarco PE.

Diabetes Care. 2006 Feb;29(2):471. No abstract available.

PMID:
16443920
7.

An easy sliding scale formula.

Denker PS, Leonard DR, DiMarco PE, Maleski PA.

Diabetes Care. 1995 Feb;18(2):278. No abstract available.

PMID:
7729314
8.

Fasting serum insulin levels in essential hypertension. A meta-analysis.

Denker PS, Pollock VE.

Arch Intern Med. 1992 Aug;152(8):1649-51.

PMID:
1386725
9.

Hyperthyroidism with a low radioactive iodine uptake.

Denker PS.

Arch Intern Med. 1991 Nov;151(11):2326, 2330. No abstract available.

PMID:
1953242
10.

Effect of pro-atrial natriuretic peptides 1-30, 31-67 and 99-126 on angiotensin II-stimulated aldosterone production in calf adrenal cells.

Denker PS, Vesely DL, Gómez-Sánchez CE.

J Steroid Biochem Mol Biol. 1990 Nov 30;37(4):617-9.

PMID:
2149056
11.

Hypernephroma associated with multiple endocrine neoplasia type I: a case report.

Denker PS, Wright D, Hilscher JR, Saba SR, Ramirez G.

J Urol. 1986 Oct;136(4):896-8.

PMID:
2876110

Supplemental Content

Loading ...
Support Center